Feb 8 | News
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|
Feb 1 | News
The longtime executives are leaving after a 2 1/2-year span that's seen two dozen recalls of Tylenol, Motrin, Zyrtec and other nonprescription drugs and a congressional investigation of the handling of the recalls.
|
Jan 24 | News
Johnson & Johnson said Tuesday that fourth-quarter profit was barely a tenth of what it made a year ago as several charges for recalls, litigation and an acquisition dragged down income.
|
Dec 16 2011 | News
Swiss orthopedics maker Synthes says its investors overwhelmingly voted to accept a $21.3 billion acquisition offer from U.S. health care conglomerate Johnson & Johnson.
|
Dec 9 2011 | News
Johnson & Johnson’s Janssen Biotech unit announced Thursday that it entered into an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765, in a deal valued at as much as $975 million for Pharmacyclics.
|
Dec 9 2011 | News
Federal inspectors say the contract manufacturer for Johnson & Johnson's cancer drug Doxil hasn't been maintaining equipment or promptly investigating defective product batches and other serious problems at its Bedford, Ohio, factory.
|
Nov 21 2011 | News
NEW YORK (AP) — Cancer patients relying on Johnson & Johnson's drug Doxil could continue facing shortages after a contract manufacturer suspended operations at its Ohio plant, according to The Wall Street Journal.
|
Nov 16 2011 | News
NEW YORK (AP) — Gilead Sciences Inc. and Johnson & Johnson's Tibotec unit said Tuesday they will collaborate to develop a new HIV pill that combines Tibotec's Prezista with Gilead's drug Emtriva and two experimental drugs.
|
Oct 18 2011 | News
Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.
|
Oct 6 2011 | News
J&J unit Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR (nesiritide), a prescription medication for patients with heart failure.
|